Teva Pharmaceuticals USA v. Sandoz Inc., No. 12-1567 (Fed. Cir. July 26, 2013)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

The defendants in thes e consolidated patent i n- fringement actions (collectively, Appellants) appeal from the district court’s judgment that various claims of the nine patents-in-suit asserted by the plaintiffs (collectively, Teva) are infringed, and from the court’s holdings regard- ing indefiniteness, nonenablement, and obviousness.